Lercanidipina Generis

Lercanidipine, the active ingredient in Lercanidipina Generis, is a calcium channel blocker presented as an oral dosage form for oral use. It is employed to lower elevated blood pressure in adults diagnosed with hypertension. GNH USA supplies Lercanidipina Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine acts on the vascular smooth muscle to manage high blood pressure conditions. - Hypertension: reduces systolic and diastolic pressure in patients with essential hypertension. - Isolated systolic hypertension: lowers elevated systolic readings in older adults. - High‑risk cardiovascular patients: contributes to overall blood pressure control as part of a comprehensive antihypertensive regimen.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: sensation of warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Fatigue or general weakness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Angioedema: swelling of face, lips, or throat. - Myocardial infarction: rare occurrence of heart attack. - Hepatic enzyme elevation: abnormal liver function tests. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac conduction disturbances: heart block or arrhythmias.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic impairment: dose adjustment may be required in patients with liver dysfunction. - Concomitant antihypertensives: assess for additive blood‑pressure‑lowering effects. - Heart failure: use with caution; monitor for worsening symptoms. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension. - Co‑administration with other calcium‑channel blockers: can lead to additive vasodilatory effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Beta‑blockers: monitor for bradycardia or excessive blood‑pressure reduction. - Diuretics: watch for electrolyte imbalances and enhanced hypotensive response.